Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L. Moore, Karina Butler et al.|PLoS ONE|2018Cited by 29
Clinical validation of a quantitative HIV-1 DNA droplet digital PCR assay: Applications for detecting occult HIV-1 infection and monitoring cell-associated HIV-1 dynamics across different subtypes in HIV-1 prevention and cure trialsLaura Powell, Deborah Persaud, Adit Dhummakupt et al.|Journal of Clinical Virology|2021Cited by 19
Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsySimona Balestrini, Fiona Byrne, Matthias J. Koepp et al.|Epilepsy & Behavior|2020Cited by 16
A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key PopulationsEsther Fearnhill, Dominique Costagliola, Annabelle Gourlay et al.|Clinical Infectious Diseases|2017Cited by 13
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIVOliver Stirrup, Mark Hopkins, Caroline Sabin et al.|Journal of Virus Eradication|2019Cited by 11